Survey data of COVID-19 vaccine side effects among Qassim University members
DOI:
https://doi.org/10.18203/2349-3933.ijam20220381Keywords:
COVID-19 vaccine, Side effect, Pfizer, AstraZenecaAbstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was initially reported as a culprit for many unexplained cases of pneumonia in Wuhan, China. Since then, COVID-19 vaccine is highly recommended as a protective measure of this pandemic. This study aimed to measure the safety profile of the COVID-19 vaccine among Qassim University members.
Methods: This is a cross-sectional observational study conducted among Qassim University members, Saudi Arabia. A pre-specified questionnaire was distributed among prospective members of the campus using an online survey. Participants who were vaccinated by either one or two doses were the subjects of this study. Consent was sought from the participants or next of kin and the data collection were lasted for over three months.
Results: The 604 respondents were able to recruit (51.7% males versus 48.3% females). 55.6% of respondents were in the younger age group (age ≤25 years). The most commonly received vaccine was Pfizer (67.3%) while the most common side effect was local pain at the site of injection (89.4%) and tiredness (76.7%). Females were significantly more being associated with having COVID-19 vaccine side effects, while complained about fever was significantly higher in the AstraZeneca vaccine (p<0.001).
Conclusions: Our findings were consistent with literatures, our study finds local pain at the site of injection, tiredness, muscle pain, headache and fever as the most common side effects of the COVID-19 vaccine. The side effects of the COVID-19 vaccine had a greater impact on female respondents than their male counterparts.
References
UpToDate: Evidence-based Clinical Decision Support. Wolters Kluwer. Available at: https://www.uptodate.com. Accessed on 14 November 2021.
World Health Organization. Draft landscape of COVID-19 candidate vaccines. 2020. Available at: https://www.who.int/publications/m/item/draft–land scape-of-covid-19-candidate -vaccines. Accessed on 14 November 2021.
Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020;383:2427-38.
Baden LR, Sahly HME, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403-16.
Covidvax live. Live COVID-19 vaccination tracker: Saudi Arabia. 2021. Available at: https://covid vax.live/location/sau. Accessed on 14 October 2021.
Ahsan W, Syed NK, Alsraeya AA, Alhazmi HA, Najmi A, Al Bratty M, et al. Post-vaccination survey for monitoring the side effects associated with COVID-19 vaccines among healthcare professionals of Jazan province, Saudi Arabia. Saudi Med J. 2021;42(12):1341-52.
Alhazmi A, Alamer E, Daws D, Hakami M, Darraj M, Abdelwahab S, Maghfuri A, Algaissi A. Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia. Vaccines. 2021;9(6):674.
Riad A, Sağıroğlu D, Üstün B, Pokorná A, Klugarová J, Attia S, Klugar M. Prevalence and risk factors of CoronaVac side effects: an independent cross-sectional study among healthcare workers in Turkey. J Clin Med. 2021;10(12):2629.
Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111:219-26.
Riad A, Pokorná A, Klugarová J, Antalová N, Kantorová L, Koščík M, Klugar M. Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18–30 Years Old): An Independent Post-Marketing Study. Pharmaceuticals. 2021;14(10):1049.
Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J Clin Med. 2021;10(7):1428.
Djanas D, Martini RD, Putra H, Zanir A, Nindrea RD. Survey data of COVID-19 vaccine side effects among hospital staff in a national referral hospital in Indonesia. Data in brief. 2021;36:107098.
